In 2008, the company raised $25 Million in a Series A financing round led by Alta Partners, Polaris Ventures, New Enterprise Associates, Healthcare Ventures, and Yasuda Economic Development Corporation [REF].
In early 2009, Trevena entered into a collaborative agreement with Ligand Pharmaceuticals to identify biased ligands at numerous GPCRs from a large, diverse chemical library [REF].